Carey Brenna, DeLay Monica, Strasser Jane E, Chalk Claudia, Dudley-McClain Kristen, Milligan Gregg N, Brunner Hermine I, Thornton Sherry, Hirsch Raphael
William S. Rowe Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Clin Immunol. 2005 Jul;116(1):65-76. doi: 10.1016/j.clim.2005.02.013.
CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to beta2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.
CD8 + T淋巴细胞识别与I类主要组织相容性复合体（MHC）结合的肿瘤和病毒抗原。肿瘤和病毒可能通过阻止抗原呈递来逃避检测。本研究旨在确定一种可溶性二价融合蛋白，其包含与β2-微球蛋白融合的I类MHC分子的细胞外结构域和IgG1的恒定结构域，是否能在体内诱导免疫反应。给小鼠注射负载肿瘤肽的融合蛋白可诱导肽特异性T细胞活化并延缓肿瘤生长。给小鼠注射负载源自单纯疱疹病毒1型（HSV-1）的糖蛋白B（gB）肽的融合蛋白可诱导gB特异性细胞毒性T淋巴细胞，并保护小鼠免受致死性HSV-1攻击。这些数据表明，在抗原呈递改变的情况下，负载抗原的MHC / IgG融合蛋白可能增强T细胞免疫。
